Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...
Arcapita is a global alternative investments firm focused on private equity and real estate, with a track record of over 30 years and a total transaction value of more than $32 billion. Arcapita has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback